Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Invicorp; Phentolamine/aviptadil; PSD 510; Vasopotin

Latest Information Update: 20 Apr 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Senetek
  • Developer Evolan Pharma; Plethora Solutions; Senetek
  • Class Gastrointestinal hormones; Imidazoles; Neuropeptides; Peptide hormones; Vasodilators
  • Mechanism of Action Alpha adrenergic receptor antagonists; Vasoactive intestinal peptide receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erectile dysfunction

Most Recent Events

  • 20 Apr 2017 Launched for Erectile dysfunction in Finland (Intracavernous) before April 2017 (Fimea website, April 2017)
  • 20 Apr 2017 No recent reports on development identified - Preregistration for Erectile dysfunction in Germany (Intracavernous)
  • 03 Apr 2015 Preregistration for Erectile dysfunction in United Kingdom, Germany, Sweden, Finland and Norway (Intracavernous) before April 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top